Skip to main navigation
Skip to search
Skip to main content
WashU Medicine Research Profiles Home
Help & FAQ
Home
Profiles
Departments, Divisions and Centers
Research output
Search by expertise, name or affiliation
Potential Expanded Indications for Neprilysin Inhibitors
Elizabeth Riddell
,
Justin M. Vader
Division of Cardiology
Institute of Clinical and Translational Sciences (ICTS)
Research output
:
Contribution to journal
›
Review article
›
peer-review
25
Scopus citations
Overview
Fingerprint
Fingerprint
Dive into the research topics of 'Potential Expanded Indications for Neprilysin Inhibitors'. Together they form a unique fingerprint.
Sort by
Weight
Alphabetically
Keyphrases
Expanded Indication
100%
Angiotensin Receptor-neprilysin Inhibitor
100%
Sacubitril-valsartan
66%
Randomized Trial
33%
Noncardiovascular Disease
33%
Trial Data
16%
New Therapeutic Strategies
16%
Renal Function
16%
Heart Failure
16%
Heart Failure with Preserved Ejection Fraction (HFpEF)
16%
Left Ventricular Ejection Fraction
16%
Clinical Impact
16%
Acute Heart Failure
16%
Enalapril
16%
Cardiovascular System
16%
Post-myocardial Infarction
16%
Therapeutic Action
16%
Potential Therapeutics
16%
System Function
16%
Acute Decompensated Heart Failure
16%
Neurological Function
16%
Systolic Dysfunction
16%
Mechanistic Data
16%
NYHA Class
16%
RAAS Inhibition
16%
PARADIGM-HF
16%
Pharmacology, Toxicology and Pharmaceutical Science
Enkephalinase Inhibitor
100%
Membrane Metalloendopeptidase
100%
Valsartan/Sacubitril
100%
Congestive Heart Failure
50%
Cardiovascular Disease
50%
Combination Therapy
25%
Heart Infarction
25%
Enalapril
25%
Acute Heart Failure
25%
Systolic Dysfunction
25%
Heart Failure with Preserved Ejection Fraction
25%